Department of oral and craniomaxillofacial surgery, center for dental medicine, university medical center Freiburg, Hugstetter Straße 55, 79106 Freiburg, Germany.
Department of oral and craniomaxillofacial surgery, center for dental medicine, university medical center Freiburg, Hugstetter Straße 55, 79106 Freiburg, Germany.
J Stomatol Oral Maxillofac Surg. 2017 Sep;118(4):232-235. doi: 10.1016/j.jormas.2017.06.012. Epub 2017 Jul 8.
Antiresorptive agents are widely used in catabolic bone diseases. Not only bisphosphonates but also new drugs like Denosumab may induce osteonecrosis of the jaw as a side effect. The present review describes the current effect mechanisms of commonly used antiresorptives, pathogenetic theories for the development of antiresorptive-related osteonecrosis of the jaw (ARONJ), and potential risk factors. Furthermore, diagnostic modalities and treatment options as well as new and innovative strategies are discussed. The major key factor to avoid the occurrence of ARONJ still remains the implementation of throughout preventive measures.
抗吸收药物广泛用于分解代谢性骨疾病。不仅双膦酸盐，而且新型药物如地舒单抗也可能引起颌骨坏死作为副作用。本综述描述了常用抗吸收药物的当前作用机制、抗吸收相关颌骨坏死（ARONJ）的发病理论以及潜在的危险因素。此外，还讨论了诊断方法和治疗选择以及新的创新策略。避免发生 ARONJ 的主要关键因素仍然是全面实施预防措施。
